Company Overview
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia. Annovis Bio, Inc. was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -51.85% |
| 6 Months: | -49.42% |
| 3 Months: | -27.37% |
| 1 Month: | -30.85% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)25.36 · Oversold
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 74.5% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ANVS Annovis Bio, Inc. PHARMA | 1.30 | -0.74 | $55.39M | 0.00% | - | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | 0 | - | - | 0 | - | - | 0 | - | - | 0 | - | - | 0 | - | - | 0 | - | - | 0 |
| Operating Income | -186.79K | -306.08K | -241.79K | -583.16K | -2.54M | -1.60M | -3.23M | -2.53M | -2.85M | -5.25M | -5.97M | -6.48M | -9.97M | -9.76M | -14.86M | -7.81M | -7.76M | -4.39M | -6.28M | -6.27M | -7.43M | -18.01M |
| Net Income | -190.90K | -344.70K | -254.12K | -441.59K | -2.31M | -1.01M | -3.20M | -2.52M | -2.85M | -5.23M | -5.94M | -6.43M | -9.74M | -9.54M | -14.72M | -1.07M | -5.02M | -12.64M | -5.54M | -6.22M | -7.26M | -17.61M |
| Diluted EPS | - | - | - | - | - | -0.15 | -0.46 | -0.34 | -0.35 | -0.64 | -0.73 | -0.79 | -1.07 | -1.07 | -1.63 | -0.72 | -0.44 | -0.97 | -0.32 | -0.32 | -0.37 | -0.63 |
| R&D Expense | 6.02K | 6.04K | 2.01K | 66.45K | 856.48K | 718.90K | 2.39M | 1.82M | 1.38M | 2.15M | 4.03M | 4.12M | 7.79M | 8.26M | 13.84M | 6.51M | 5.79M | 2.69M | 5.01M | 5.16M | 6.29M | 16.72M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -1.61M | -6.64M | -14.54M | -25.51M | -45.04M | -26.69M | -29.70M |
| Net Income | -990.98K | -5.46M | -14.49M | -25.33M | -56.20M | -24.59M | -28.85M |
| Diluted EPS | - | -0.87 | -1.90 | -3.10 | -6.23 | -2.31 | -1.40 |
| R&D Expense | 776.26K | 3.05M | 8.48M | 16.52M | 38.79M | 20.00M | 25.22M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 1.12M | 8.12M | 46.00M | 44.10M | 39.97M | 37.12M | 36.02M | 10.21M | 13.93M | 21.08M |
| Total Equity | -7.59M | -8.58M | 7.54M | 44.49M | 42.70M | 38.67M | 34.59M | 28.32M | -7.75M | 9.31M | 16.85M |
| Cash & Equivalents | - | 1.86K | 8.07M | 45.69M | 42.67M | 35.97M | 31.99M | 28.38M | 5.75M | 10.55M | 19.53M |
| Total Liabilities | - | 2.62M | 578.38K | 1.51M | 1.40M | 1.30M | 2.53M | 7.70M | 17.96M | 4.62M | 4.23M |
| Current Liabilities | - | 2.01M | 578.38K | 1.51M | 1.40M | 1.30M | 2.53M | 7.70M | 4.28M | 3.88M | 3.64M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -476.54K | -3.97M | -9.13M | -17.31M | -39.97M | -21.89M | -25.62M |
| Financing Cash Flow | 443.09K | 12.04M | 46.74M | 4.61K | 17.34M | 26.69M | 34.60M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - |
| ROE % | 11.6% | -72.4% | -32.6% | -89.4% | 725.1% | -264.2% | -171.2% |
| ROCE % | 179.7% | -88.1% | -32.7% | -90.1% | -759.6% | -265.8% | -170.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Empery Asset Management, LP | 5.63% | 2.40M | $2.74M |
| 2 | Marshall Wace LLP | 4.32% | 1.84M | $2.10M |
| 3 | Vanguard Capital Management LLC | 3.86% | 1.65M | $1.88M |
| 4 | Tudor Investment Corp Et Al | 3.18% | 1.36M | $1.55M |
| 5 | Renaissance Technologies, LLC | 2.35% | 1.00M | $1.14M |
| 6 | Two Sigma Investments, LP | 1.36% | 579.57K | $660.71K |
| 7 | Geode Capital Management, LLC | 0.67% | 283.82K | $323.55K |
| 8 | Blackrock Inc. | 0.59% | 249.86K | $284.83K |
| 9 | Citadel Advisors Llc | 0.57% | 243.68K | $277.80K |
| 10 | Vanguard Fiduciary Trust Co | 0.42% | 177.53K | $202.38K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ANVS
Annovis Bio (ANVS) Loses 26.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Annovis Bio (ANVS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates …
Annovis Bio Targets March 2027 Alzheimer’s Readout, Prepares Rolling NDA
Annovis Bio (NYSE:ANVS) said it expects to report top-line results from the six-month portion of its pivotal Phase III Alzheimer’s disease trial in March 2027, while preparing a rolling new drug application, or NDA, that management said cou…
Annovis to Host Corporate Update Webinar on September 2, 2026
MALVERN, Pa., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative disea…
The Next Billion-Dollar Opportunity in Alzheimer's Disease Market: 6 Pipeline Therapies to Watch | DelveInsight
The Alzheimer's disease treatment landscape is experiencing a major transformation with the introduction of disease-modifying therapies that target fundamental disease mechanisms, particularly amyloid-β pathology. Among these, LEQEMBI (leca…
Annovis Bio Enrolls Over 850 Patients for Its Next Alzheimer's Disease Trial
Annovis Bio's Sarah MacCallum and Cheng Fang joins Ashley Mastronardi on NYSE Live to discuss the next alzheimers disease trial
Annovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer’s Disease
Pivotal Phase 3 trial enrolls 850 patients, exceeding original projections Study completion on track: symptomatic data readout - Q1 2027, disease-modifying data readout - Q1 2028 Company positions for two NDA submissions following each read…
ANVS — Frequently Asked Questions
What is the current share price of Annovis Bio, Inc. (ANVS)?
As of 2026-09-19 21:16 PDT, Annovis Bio, Inc. (ANVS) trades at $1.30 on NYSE. Its 52-week range is $1.30 to $5.10.
What is the market capitalisation of ANVS?
Annovis Bio, Inc. (ANVS) has a market capitalisation of $55.39M on NYSE.
What is the P/E ratio of ANVS?
ANVS trades at a trailing price-to-earnings (P/E) ratio of -0.74. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is -12.20.
Is ANVS a good stock to buy?
This page provides a data-driven analysis of Annovis Bio, Inc. (ANVS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.